Compare Amphastar Pharmaceuticals Inc (AMPH) vs H2O America (HTO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs H2O America — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while H2O America trades at $61.47 (market cap $2.57B). The key difference: H2O America is far larger — about 3.1× Amphastar Pharmaceuticals Inc's market cap, and H2O America pays a 2.86% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | HTO | |
|---|---|---|
Market Cap | $826.08M | $2.57B |
Sector | Health | Technology |
52-Week High | $30.81 | $62.42 |
52-Week Low | $16.87 | $44.44 |
Enterprise Value | $1.22B | $4.29B |
Dividend Yield | — | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
HTO trades at $61.47, showing minimal daily movement (+0.02%) with strong technical bullish signals from moving averages. The company maintains solid fundamentals with 12.87% net income margin and recent Q1 2026 earnings beat. Analyst consensus is strongly bullish with 80% buy ratings and a $61.33 price target, while the company continues its dividend program with a $0.44 H1-26 payment.
HTO presents a stable investment case with consistent profitability and dividend payments, though growth appears moderate. Key risks include execution of the $2.7 billion capex plan and competitive pressures in the utilities sector. The stock's current valuation appears reasonable with P/E of 21.05, suggesting potential for steady returns rather than explosive growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →
